FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
Cypherpunk's Leap Therapeutics subsidiary aligns with FDA on Phase 3 trial for sirexatamabAug 12Quarterly updateCypherpunk Technologies Inc.
BeiGene's LBL-007/tislelizumab colorectal cancer trial posts resultsJun 30Trial updatealcestobartBeiGene
Sign inSign in